排序方式: 共有86条查询结果,搜索用时 15 毫秒
81.
Spizzo G Obrist P Ensinger C Theurl I Dünser M Ramoni A Gunsilius E Eibl G Mikuz G Gastl G 《International journal of cancer. Journal international du cancer》2002,98(6):883-888
To assess the frequency and prognostic impact of Ep-CAM and Her-2/neu overexpression in patients with breast cancer and to determine its relationship with other prognostic markers, 205 breast cancer patients with a median follow-up of 10.8 years were enrolled in this retrospective study. Overexpression of Ep-CAM and Her-2/neu in tumor tissue samples was assessed by immunohistochemistry. Tumors presenting a Her-2/neu 2+ staining were additionally analyzed by FISH to exclude false positive results. Ep-CAM and Her-2/neu overexpression was found in 35.6% and 19.5% of the tumor samples, respectively. Both Ep-CAM and Her-2/neu overexpression were predictive for poor disease-free (DFS) and disease-related overall survival (DROS). Concurrent Ep-CAM and Her-2/neu overexpression was present in 13.2% of tumor specimens and had an additive negative impact on DFS and DROS. This minority of patients had a median time to relapse of only 34 months, whereas the median time to relapse was not reached in the patient population without Her-2/neu and Ep-CAM overexpression. By multivariate analysis Ep-CAM overexpression proved to be an indicator of poor prognosis, independent of tumor size, histologic grade, hormone receptor expression and Her-2/neu overexpression. In conclusion, overexpression of Ep-CAM and Her-2/neu complement each other as predictors for poor prognosis in patients with invasive breast cancer. Determination of these tumor markers should help in assigning breast cancer patients to 1 of 3 distinct risk categories. 相似文献
82.
83.
Functional significance of the activation-associated receptors CD25 and CD69 on human NK-cells and NK-like T-cells 总被引:7,自引:0,他引:7
The application of autologous ex-vivo expanded cytotoxic lymphocytes to cancer patients may help to control minimal residual disease. However, the number of effector cells and the resulting antitumoral activity that can be generated in vitro are remarkably variable. Thus, we separately assessed the proliferative and cytotoxic potential of CD56+ CD3- natural killer (NK) and CD56+ CD3+ T-cells in relation to their expression of CD25, CD69, and CD16 in vitro. Two-week lymphocyte cultures from peripheral blood (n = 51) and from G-CSF-mobilized progenitor cell harvests (n = 11) were performed repeatedly from 14 women with breast cancer throughout conventional- and high-dose chemotherapy. A large proportion of CD25+ cells on day 7 of the culture predicted high expandability (r = 0.69, p < 0.00001), while elevated expression of CD69 predicted augmented cytotoxicity (r = 0.72; p = 0.00001) and low expandability (r = -0.69, p < 0.00001). CD25 and CD69 expression were inversely correlated (r = -0.8, p < 0.0001). CD16 expression was not suited to predict functional properties. Additionally, NK-cells were sorted by FACS according to CD25 versus CD69 expression. In a [3H]thymidine incorporation assay the CD25+ NK-cell fraction exhibited a higher proliferation rate than did the CD69+ fraction in all of three experiments. Together, our data suggest that CD69 is a useful marker for cytotoxic activity of NK cells, whereas proliferative potential is indicated by CD25 expression. These findings should help optimizing the ex-vivo generation of large numbers of cytotoxic effector cells for immunotherapy. 相似文献
84.
Maurus Locher Michael Steurer Emina Jukic Markus A. Keller Friedrich Fresser Carmen Ruepp Ewald Wöll Irmgard Verdorfer Günther Gastl Wolfgang Willenbacher Roman Weger David Nachbaur Dominik Wolf Eberhard Gunsilius Johannes Zschocke Normann Steiner 《American journal of hematology》2020,95(12):1562-1571
Hyperdiploidy (HRD) and specific immunoglobulin heavy locus (IGH) translocations are primary chromosomal abnormalities (CA) in multiple myeloma (MM). In this retrospective study of 794 MM patients we aimed to investigate clinical features and common CA including gain(1q) in separate subgroups defined by primary CA. In the entire group, we confirmed that gain(1q) was associated with short time to next treatment and adverse overall survival (OS). The impact was worse for four or more copies of 1q21 as compared to three copies. However, in a subgroup of patients with clonal gain(11q) and without known primary IGH translocations (CG11q), already three copies of 1q21 were associated with a poor outcome; in the absence of gain(1q), patients in this subgroup had a remarkably long median OS of more than nine years. These cases were associated with HRD, coexpression of CD56 and CD117, male gender, and IgG subtype. In non-CG11q patients, four or more copies of 1q21 (but not three copies) had a significant adverse impact on outcome. Several associations with CA and clinical findings were observed for the defined subgroups. As an example, we found a predominance of early tetraploidy, plasma cell leukemia, and female gender in the t(14;16) subgroup. Our results underscore the importance of subgrouping in MM. 相似文献
85.
Lena Horvath Georg Oberhuber reas Chott Maria Effenberger Herbert Tilg Eberhard Gunsilius Dominik Wolf Sarah Iglseder 《World journal of gastroenterology : WJG》2020,26(47):7584-7592
BACKGROUNDEnteropathy-associated T cell lymphoma (EATL) is an aggressive intestinal T cell lymphoma derived from intraepithelial lymphocytes, which occurs in individuals with celiac disease (CD). Cerebral involvement is an extremely rare condition and as described so far, lymphoma lesions may present as parenchymal predo-minantly supratentorial or leptomeningeal involvement. We describe a case of EATL with multifocal supra- and infratentorial brain involvement in a patient with refractory celiac disease (RCD).CASE SUMMARYA 58-years old man with known CD developed ulcerative jejunitis and was diagnosed with RCD type II. Six months later he presented with subacute cerebellar symptoms (gait ataxia, double vision, dizziness). Cranial magnetic resonance imaging (MRI) revealed multifocal T2 hyperintense supra- and infratentorial lesions. Laboratory studies of blood and cerebrospinal fluid were inconspicuous for infectious, inflammatory or autoimmune diseases. 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (18FDG-PET/CT) scan showed a suspect hypermetabolic lesion in the left upper abdomen and consequent surgical jejunal resection revealed the diagnosis of EATL. During the diagnostic work-up, neurological symptoms aggravated and evolved refractory to high-dosage cortisone. Recurrent MRI scans showed progressive cerebral lesions, highly suspicious for lymphoma and methotrexate chemotherapy was initiated. Unfortunately, clinically the patient responded only transiently. Finally, cerebral biopsy confirmed the diagnosis of cerebral involvement of EATL. Considering the poor prognosis and deterioration of the performance status, best supportive care was started. The patient passed away three weeks after diagnosis.CONCLUSIONEATL with cerebral involvement must be considered as a possible differential diagnosis in patients with known RCD presenting with neurological symptoms. 相似文献
86.
Auberger J Clausen J Willenbacher W Erdel M Gunsilius E Petzer A Gastl G Nachbaur D 《International journal of hematology》2008,87(4):382-386
Disease recurrence has been and remains the leading cause of treatment failure in patients with high-risk leukemia.We retrospectively
analyzed outcome in 61 patients with high-risk leukemia receiving a combination of fludarabine and intermediate-dose cytarabine
as induction (n = 11) or salvage therapy (n = 35). Thirty-six patients having a suitable stem cell donor proceeded to allogeneic hematopoietic stem cell transplantation
(HSCT). Ten patients received fludarabine-based salvage therapy without consecutive allogeneic transplantation and 15 patients
received fludarabine/intermediate-dose cytarabine because of disease relapse following allogeneic stem cell transplantation.
In patients without prior allogeneic HSCT (n = 46) the complete remission rate (CR) was 41% with a CR rate of 46 and 14% in patients with acute myeloid leukemia (AML)
and with acute lymphoblastic leukemia (ALL), respectively. Overall survival for patients achieving a CR was 41 versus 0% for
patients not achieving CR (P < 0.0001). The best outcome was observed in patients receiving an allogeneic HSCT in CR following fludarabine/intermediate-dose
cytarabine (47 vs. 0% for patients not in CR at the time of allografting, P = 0.01). All 10 patients receiving fludarabine/intermediate-dose cytarabine without subsequent allogeneic HSCT died within
3 years either of disease relapse/progression or infection. Only 1/15 (7%) patients receiving fludarabine/intermediate-dose
cytarabine because of relapse following allogeneic HSCT became a long-term survivor. By multivariate analysis achieving CR,
receiving an allogeneic HSCT, and being in first relapse or untreated were the only parameters that significantly determine
the outcome. Although preliminary only high-risk AML patients having a stem cell donor are candidates for fludarabine/intermediate-dose
cytarabine and only those achieving a CR should be referred to subsequent allogeneic HSCT. All other patients with high-risk
leukemia are candidates for experimental therapies within controlled trials. 相似文献